Marksans Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Marksans Pharma Ltd reported a 15.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 22.9%.
• Its expenses for the quarter were up by 10.8% QoQ and 13.5% YoY.
• The net profit increased 31.1% QoQ and increased 64.3% YoY.
• The earnings per share (EPS) of Marksans Pharma Ltd stood at 3.27 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Marksans Pharma Ltd is a pharmaceutical company renowned for its extensive range of pharmaceutical products. The company operates primarily within the pharmaceutical industry, focusing on the development, manufacturing, and distribution of a wide array of pharmaceutical formulations. Marksans Pharma Ltd's offerings include tablets, capsules, ointments, and other formulations, catering to various therapeutic segments. The company has established a global presence with a significant market footprint in several countries. While specific recent major developments are not provided in the current dataset, the company's ongoing operations reflect its commitment to innovation and expansion in the pharmaceutical sector.

Revenue

During the fourth quarter of fiscal year 2026 (Q4FY26), Marksans Pharma Ltd reported a total income of ₹891.29 crores, which represents a 15.1% increase compared to the previous quarter (Q3FY26), where the total income stood at ₹774.57 crores. Year-over-year, the total income experienced a substantial growth of 22.9% from ₹724.98 crores in the fourth quarter of fiscal year 2025 (Q4FY25). This upward trend in revenue highlights an increase in the company's income generation over both the quarterly and annual periods.

Profitability

The profitability of Marksans Pharma Ltd saw significant improvements in Q4FY26. The company registered a profit before tax of ₹200.00 crores, marking a 32.8% increase from ₹150.62 crores in Q3FY26 and a notable 72.3% rise from ₹116.09 crores in Q4FY25. The profit after tax for Q4FY26 was ₹149.03 crores, which is a 31.1% increase from the previous quarter's ₹113.69 crores and a 64.3% surge from ₹90.73 crores in Q4FY25. The earnings per share (EPS) for this quarter was ₹3.27, demonstrating a 30.8% growth from ₹2.50 in Q3FY26 and a 63.5% increase from ₹2.00 in Q4FY25. These figures indicate a robust enhancement in profitability metrics over the examined periods.

Operating Metrics

The operating expenses of Marksans Pharma Ltd for Q4FY26 amounted to ₹691.29 crores, reflecting a 10.8% increase from ₹623.95 crores in Q3FY26 and a 13.5% rise from ₹608.88 crores in Q4FY25. The tax expense for the quarter was ₹50.97 crores, which increased by 38.0% from the previous quarter's ₹36.93 crores and doubled from ₹25.37 crores in Q4FY25 by 100.9%. The financial data does not provide specific details on operational efficiency ratios or liquidity metrics, such as the current ratio or debt-to-equity ratio. However, the consistent increase in both income and expenses suggests a dynamic operational environment for Marksans Pharma Ltd.